tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2014-2-3-10tumors-102Research ArticleФУНДАМЕНТАЛЬНАЯ ОНКОЛОГИЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАFUNDAMENTAL ONCOLOGY AND EXPERIMENTAL MEDICINEВЛИЯНИЕ СРОКОВ ВЫПОЛНЕНИЯ ОТСРОЧЕННОЙ ОРХИФУНИКУЛЭКТОМИИ НА ВЫЖИВАЕМОСТЬ БОЛЬНЫХ С РАСПРОСТРАНЕННЫМИ ГЕРМИНОГЕННЫМИ ОПУХОЛЯМИ ЯИЧКАThe impact of time of performance of delayed orchiectomy on survival of patients with advanced germ cell tumors of testiclesФедянинМ. Ю.FedyaninM. Yu.

Контактная информация: Федянин Михаил Юрьевич —  к.м.н.,  врач-онколог отделения клинической фармакологии и химиотерапии ФГБУ «Российский онкологический научный  центр  им. Н. Н. Блохина. Россия, г. Москва, Каширское шоссе 24, +7 (499) 324-19-00, fedianinmu@mail.ru

fedianinmu@mail.ruТрякинА. А.TryakinA. A.atryakin@mail.ruБулановА. А.BulanovA. A.a_bulanov@mail.ruФайнштейнИ. А.FainshteinI. A.yurisergeevmd@mail.ruСергеевЮ. С.SergeevYu. S.yurisergeevmd@mail.ruМатвеевВ. Б.MatveevV. B.vsevolodmatveev@mail.ruГаринА. М.GarinA. M.agarin@mail.ruТюляндинС. А.TyulyandinS. A.

Тюляндин Сергей Алексеевич — д.м.н.,  профессор, заведующий отделением клинической фармакологии и химиотерапии

stjulandin@mail.ruРоссийский онкологический научный центр им. Н. Н. БлохинаRussian Federation20142105201502310Copyright © Федянин М.Ю., Трякин А.А., Буланов А.А., Файнштейн И.А., Сергеев Ю.С., Матвеев В.Б., Гарин А.М., Тюляндин С.А., 20152015Федянин М.Ю., Трякин А.А., Буланов А.А., Файнштейн И.А., Сергеев Ю.С., Матвеев В.Б., Гарин А.М., Тюляндин С.А.Fedyanin M.Y., Tryakin A.A., Bulanov A.A., Fainshtein I.A., Sergeev Y.S., Matveev V.B., Garin A.M., Tyulyandin S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/102Цель

Цель:  изучение влияния сроков выполнения отсроченной орхидфуникулэктомии (ОФЭ) на общую выживаемость больных с распространенными  герминогенными  опухолями яичка, у которых ОФЭ не была выполнена перед началом лечения.

Материалы и методы

Материалы и методы: с 1986 по 2010 года в отделении клинической фармакологии и химиотерапии 71 из 1486  (4,8%) больному выполнена отсроченная  ОФЭ. В течение 1 курса ХТ  —  39 (55%) больным, во время 2–4 курса —  21 (29,6%), по завершении ХТ  —  11 (15,5%). Медиана наблюдения составила 156 месяцев. Основным критерием оценки являлась общая выживаемость больных.

Результаты

Результаты:  при гистологическом исследовании удаленного яичка было выявлено, что жизнеспособная герминогенная опухоль встречалась  у 25 (64,1%)  больных в случае удалении яичка на 1 курсе  иХТ, у 10 (47,7%) больных  — в процессе 2–4 курса  иХТ, 0 — после  иХТ. При этом 3-летняя ОВ больных, которым была выполнена ОФЭ на 1 курсе, составила 67%, в течение ХТ после 1 курса — 38,5%, по окончании ХТ — 88%.

Выводы

Выводы:  выполнение ОФЭ симультанно с удалением других проявлений болезни после окончания иХТ не  ухудшает показатели выживаемости.

Aim: To investigate the impact of time of performance of delayed orchiectomy on overall survival of patients with advanced germ cell tumors of testicle who didn’t undergo surgery before starting of treatment.Materials and methods: From 1986 to 2010 in the department of clinical pharmacology and chemotherapy 71 (4,8%) of 1486 patients underwent delayed orchiectomy. During the first course of chemotherapy (1st group) 39 (55%) patients underwent surgery, 21 (29,6%) patients - during 2nd -4th courses (2nd group), after the ending of chemotherapy – 11 (15,5%) patients (3rd group).Results: Final histological investigation of the specimens revealed viable germ cell tumor in 25 (64,1%) patients in the 1st  group, in 10 (47,7%) patients in the 2nd group and no viable tumor in the 3rd group.Conclusion: Performance of orchiectomy simultaneously with the removal of the other sites of the tumor after chemotherapy doesn’t impair survival.

герминогенные опухолихимиотерапияотсроченная орхифуникулэктомияgerm cell tumorschemotherapydelayed orchiectomyReferencesKrege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al.: European consensus conference on diagnosis and treatment of germ cell cancer: a report of second meeting of the European Germ Cell Cancer Concensus Group (EGCCCG): part II // European urology. 2008;53:497–513.Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, et al.: European consensus conference on diagnosis and treatment of germ cell cancer: a report of second meeting of the European Germ Cell Cancer Concensus Group (EGCCCG): part II // European urology. 2008;53:497–513.Ploen L, Setchell BP. Blood-testis barriers revisited. A homage to Lennart Nicander // Int J Androl. 1991;15:1–4.Ploen L, Setchell BP. Blood-testis barriers revisited. A homage to Lennart Nicander // Int J Androl. 1991;15:1–4.Okumura K, Lee IP and Dixon RL. Permeability of selected drugs and chemicals across the blood-testis harrier of the rat // J. Phannacol. Exp. Ther. 1975 Jul;194 (1):89–95.Okumura K, Lee IP and Dixon RL. Permeability of selected drugs and chemicals across the blood-testis harrier of the rat // J. Phannacol. Exp. Ther. 1975 Jul;194 (1):89–95.Cordon-Cardo C, O’Brien JP, Casals D, Rittman GL, Biedler JL, Melamed MR, et al.: Multidrugresistance gene (P-glycoprotein) is expressed by endothelial cells at blood -brain barrier sites // Proc. Natl. Acad. Sci. 1989; 86: 695–698.Cordon-Cardo C, O’Brien JP, Casals D, Rittman GL, Biedler JL, Melamed MR, et al.: Multidrugresistance gene (P-glycoprotein) is expressed by endothelial cells at blood -brain barrier sites // Proc. Natl. Acad. Sci. 1989; 86: 695–698.International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: A prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers // J. of Clinical Oncology. 1997 Feb; Vol.15 (2):594–603.International Germ Cell Collaborative Group. International Germ Cell Consensus Classification: A prognostic Factor-Based Staging System for Metastatic Germ Cell Cancers // J. of Clinical Oncology. 1997 Feb; Vol.15 (2):594–603.Leibovich I, Little JS, Forester RS, Rowland RG, Bihrle R, Donohue JP. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors // The journal of urology. 1996 Mar;155:952–954.Leibovich I, Little JS, Forester RS, Rowland RG, Bihrle R, Donohue JP. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors // The journal of urology. 1996 Mar;155:952–954.Snow BW, Rowland RG, Donohue JP, Einhorn LH, Williams SD. Review of delayed orchiectomy in patients with disseminated testis tumors // J Urol. 1983 Mar;129 (3):522–3.Snow BW, Rowland RG, Donohue JP, Einhorn LH, Williams SD. Review of delayed orchiectomy in patients with disseminated testis tumors // J Urol. 1983 Mar;129 (3):522–3.Greist A, Einhorn LH, Williams SD, Donohue JP, Rowland RG. Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer // J Clin Oncol. 1984 Sep;2 (9):1025–7.Greist A, Einhorn LH, Williams SD, Donohue JP, Rowland RG. Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer // J Clin Oncol. 1984 Sep;2 (9):1025–7.Chong C, Logothetis CJ, von Eschenbach A, Ayala A, Samuels M. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response // J Urol. 1986 Dec;136 (6):1221–3.Chong C, Logothetis CJ, von Eschenbach A, Ayala A, Samuels M. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response // J Urol. 1986 Dec;136 (6):1221–3.Ondrus, D, Horfiak M and Matoska J. Neo-adjuvant chemotherapy with delayed orchiectomy in patients with advanced germ cell testicular cancer // Neoplasma. 1993;40 (3):189–92.Ondrus, D, Horfiak M and Matoska J. Neo-adjuvant chemotherapy with delayed orchiectomy in patients with advanced germ cell testicular cancer // Neoplasma. 1993;40 (3):189–92.Simmonds PD, Mead GM, Lee AH, Theaker JM, Dewbury K, Smart CJ. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? // Cancer. 1995 Feb 15;75 (4):1018–24.Simmonds PD, Mead GM, Lee AH, Theaker JM, Dewbury K, Smart CJ. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? // Cancer. 1995 Feb 15;75 (4):1018–24.Ondrus D, Horn k M, Breza J, Mat’oska J, Schnorrer M, Belan V, et al.: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer // Int Urol Nephrol. 2001;32 (4):665–7.Ondrus D, Horn k M, Breza J, Mat’oska J, Schnorrer M, Belan V, et al.: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer // Int Urol Nephrol. 2001;32 (4):665–7.Brown J A, Bihrle R, and. Foster RS: Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings // Urology. 2008;71: 911–914.Brown J A, Bihrle R, and. Foster RS: Delayed orchiectomy at postchemotherapy retroperitoneal lymph node dissection due to laterality of retroperitoneal metastatic pattern consistent with testicular primary: assessment of pathologic findings // Urology. 2008;71: 911–914.Fedyanin M, Tryakin A, Titov D, T. Zakharova, I. Fainstein, K. Figurin, et al.: Importance of maintenance of dose intensity (DI) during induction chemotherapy (iCT) for metastatic nonseminomatous germ cell tumors (NSGCT) // J Clin Oncol 27, 2009 (suppl; abstr e16063).Fedyanin M, Tryakin A, Titov D, T. Zakharova, I. Fainstein, K. Figurin, et al.: Importance of maintenance of dose intensity (DI) during induction chemotherapy (iCT) for metastatic nonseminomatous germ cell tumors (NSGCT) // J Clin Oncol 27, 2009 (suppl; abstr e16063).Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis // Clin Oncol (R Coll Radiol). 2008 Apr;20 (3):247–52.Ramani VA, Grey BR, Addla SK, Dunham MP, Sangar VK, Clarke NW. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis // Clin Oncol (R Coll Radiol). 2008 Apr;20 (3):247–52.

The authors declare that there are no conflicts of interest present.